Alto Neuroscience Financials - Benzinga

Alto Neuroscience Inc

ANRONYSE

Trade with Public

Trade with Public

$32.00

0.321.01%

At close: Sep 11, 5:00 PM EST

$32.00

N/A

After Hours: Sep 11, 4:00 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Alto Neuroscience Financials

Alto Neuroscience (ANRO) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Alto Neuroscience Q2 EPS $(0.65) Beats $(0.73) Estimate

Alto Neuroscience (NYSE:ANRO) reported quarterly losses of $(0.65) per share which beat the analyst consensus estimate of $(0.73) by 10.96 percent. This is unchanged from the same period last year.

Benzinga Newsdesk

PRO
Alto Neuroscience Q1 EPS $(0.80) Misses $(0.54) Estimate

Alto Neuroscience (NYSE:ANRO) reported quarterly losses of $(0.80) per share which missed the analyst consensus estimate of $(0.54) by 48.15 percent. This is a 42.86 percent decrease over losses of $(0.56) per share from

Benzinga Newsdesk

Earnings Scheduled For March 16, 2026

Benzinga Insights

PRO
Alto Neuroscience Q4 EPS $(0.45) Beats $(0.55) Estimate

Alto Neuroscience (NYSE:ANRO) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.55) by 18.77 percent. This is a 19.64 percent increase over losses of $(0.56) per share from

Benzinga Newsdesk

PRO
Alto Neuroscience Q3 EPS $(0.52) Beats $(0.67) Estimate

Alto Neuroscience (NYSE:ANRO) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.67) by 22.04 percent. This is a 16.13 percent increase over losses of $(0.62) per share from

Benzinga Newsdesk

PRO
Alto Neuroscience Q2 EPS $(0.65) Misses $(0.61) Estimate

Alto Neuroscience (NYSE:ANRO) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate of $(0.61) by 7.08 percent. This is a 8.33 percent decrease over losses of $(0.60) per share from

Benzinga Newsdesk